The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EMN 2018 | MRD in myeloma: the complementary role of imaging techniques
A picture can say a thousand words and, in this case, it is all too true; understanding tumour metabolism, bone marrow involvement and disease progression can all be captured through imaging techniques. At the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy, Elena Zamagni, MD, PhD, from the University of Bologna, Bologna, Italy, talks about the role of PET-CT and MRI in analyzing measurable residual disease (MRD) in multiple myeloma (MM). Dr Zamagni notes the questions raised on the standardization and incorporation of MRD measurement within clinical trials, and how these will be improved with further research and time.
